Content area
Abstract
POTENT S-1 trial results Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg per day). PATRICIA study results Pertuzumab combined with high-dose trastuzumab is a promising treatment for HER2-positive metastatic breast cancer with CNS metastases after CNS-directed radiotherapy, according to research by Nancy Liu (Dana-Farber Cancer Institute, Boston, MA, USA) and colleagues. Neratinib-associated diarrhoea Arlene Chan (Breast Cancer Research Centre-WA & Curtin University, Bentley, WA, Australia) and colleagues reported the results of the phase 2 CONTROL trial, investigating anti-diarrhoeal prophylaxis with or without neratinib dose escalation in patients treated with neratinib. 514 patients with stage I–IIc HER2-positive breast cancer were enrolled into one of six cohorts (four cohorts of different types of anti-diarrhoeal prophylaxis [loperamide, budesnoside, or colestipol], alone or in combination), and two cohorts of neratinib dose escalation plus loperamide.